2157.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 05:11):

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China...

Stats
Dzisiejszy wolumen	1.35M
Średni wolumen	1.84M
Kapitalizacja rynkowa	8.94B
EPS	HKD0 ( 2023-08-25 )
Następna data zysków	( HKD0 ) 2024-06-14
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-557.00
ATR14	HKD0.0510 (0.92%)

Wolumen Korelacja

Długi: -0.19 (neutral)

Krótki: -0.70 (moderate negative)

Signal:(44.995) Neutral

Lepu Biopharma Co., Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lepu Biopharma Co., Ltd. Korelacja - Waluta/Towar

0.45
( neutral )

0.37
( neutral )

0.00
( neutral )

-0.81
( strong negative )

0.39
( neutral )

0.71
( moderate )

Lepu Biopharma Co., Ltd. Finanse

Annual	2023
Przychody:	HKD225.35M
Zysk brutto:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2023
Przychody:	HKD225.35M
Zysk brutto:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2022
Przychody:	HKD15.57M
Zysk brutto:	HKD13.57M (87.12 %)
EPS:	HKD-0.420

Financial Reports:

No articles found.

Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.